Richmond Brothers Inc. decreased its position in shares of Johnson & Johnson (NYSE:JNJ – Get Rating) by 8.4% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,981 shares of the company’s stock after selling 182 shares during the period. Johnson & Johnson accounts for approximately 0.5% of Richmond Brothers Inc.’s portfolio, making the stock its 19th biggest holding. Richmond Brothers Inc.’s holdings in Johnson & Johnson were worth $350,000 at the end of the most recent quarter.
Several other institutional investors also recently added to or reduced their stakes in JNJ. Veracity Capital LLC increased its position in shares of Johnson & Johnson by 1.2% during the 4th quarter. Veracity Capital LLC now owns 5,027 shares of the company’s stock valued at $888,000 after purchasing an additional 59 shares during the period. Sandy Cove Advisors LLC increased its position in shares of Johnson & Johnson by 1.6% during the 3rd quarter. Sandy Cove Advisors LLC now owns 3,703 shares of the company’s stock valued at $605,000 after purchasing an additional 60 shares during the period. LCM Capital Management Inc grew its holdings in shares of Johnson & Johnson by 0.7% in the 4th quarter. LCM Capital Management Inc now owns 9,437 shares of the company’s stock worth $1,667,000 after acquiring an additional 61 shares during the last quarter. Arbor Investment Advisors LLC grew its holdings in shares of Johnson & Johnson by 2.3% in the 4th quarter. Arbor Investment Advisors LLC now owns 2,697 shares of the company’s stock worth $476,000 after acquiring an additional 61 shares during the last quarter. Finally, Magnolia Capital Advisors LLC grew its holdings in shares of Johnson & Johnson by 0.7% in the 3rd quarter. Magnolia Capital Advisors LLC now owns 8,883 shares of the company’s stock worth $1,451,000 after acquiring an additional 62 shares during the last quarter. Institutional investors and hedge funds own 67.94% of the company’s stock.
Insider Activity
In other Johnson & Johnson news, insider James D. Swanson sold 1,062 shares of the business’s stock in a transaction on Monday, March 6th. The shares were sold at an average price of $154.66, for a total transaction of $164,248.92. Following the sale, the insider now owns 9,215 shares of the company’s stock, valued at $1,425,191.90. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 0.20% of the stock is owned by company insiders.
Wall Street Analysts Forecast Growth
Johnson & Johnson Price Performance
JNJ opened at $160.99 on Friday. The company has a fifty day simple moving average of $158.97 and a 200 day simple moving average of $166.83. The stock has a market cap of $418.37 billion, a P/E ratio of 33.68, a P/E/G ratio of 2.77 and a beta of 0.53. The company has a quick ratio of 0.85, a current ratio of 1.07 and a debt-to-equity ratio of 0.49. Johnson & Johnson has a 12 month low of $150.11 and a 12 month high of $183.35.
Johnson & Johnson (NYSE:JNJ – Get Rating) last announced its quarterly earnings data on Tuesday, April 18th. The company reported $2.68 earnings per share for the quarter, beating the consensus estimate of $2.51 by $0.17. The company had revenue of $24.75 billion during the quarter, compared to analysts’ expectations of $23.61 billion. Johnson & Johnson had a return on equity of 36.13% and a net margin of 13.22%. Johnson & Johnson’s revenue for the quarter was up 5.6% compared to the same quarter last year. During the same quarter last year, the company earned $2.67 EPS. On average, research analysts expect that Johnson & Johnson will post 10.66 EPS for the current year.
Johnson & Johnson Increases Dividend
The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 6th. Shareholders of record on Tuesday, May 23rd will be given a dividend of $1.19 per share. The ex-dividend date is Monday, May 22nd. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.13. This represents a $4.76 annualized dividend and a yield of 2.96%. Johnson & Johnson’s dividend payout ratio (DPR) is 94.56%.
Johnson & Johnson Profile
Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.
Featured Articles
- Get a free copy of the StockNews.com research report on Johnson & Johnson (JNJ)
- Thinking Of Buying The Dip On JD.com? Consider This First
- Wynn Resorts: A Winning Bet for 2023
- A Royally Good Time To Buy The Walt Disney Company
- 3 Surprising Stocks Leading Growth Over Value
- Copa Holdings Is Looking For A Comeback, Its Dividend Agrees
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
